Strong association between herpes simplex virus-1 and chemotherapy-induced oral mucositis in patients with hematologic malignancies

다국어 초록 (Multilingual Abstract)

Background/Aims: A link between oral cavity infections and chemotherapy-induced oral mucositis (CIOM) in patients with hematological malignancies (HMs) undergoing intensive chemotherapy (IC) or hematopoietic stem cell transplantation (HSCT) has been suggested. However, conclusive data are lacking, and there are no current guidelines for the prophylactic use of antimicrobials to prevent CIOM in these populations.
Methods: The relationships between herpes simplex virus (HSV) reactivation and Candida colonization in the oral cavity and CIOM in patients with HMs undergoing IC or HSCT were evaluated. Patients aged ≥ 19 years with HMs undergoing IC or HSCT were enrolled. Each patient was evaluated for HSV and Candida in the oral cavity along with CIOM at baseline and during the 2nd, 3rd, and 4th weeks.
Results: Seventy presentations among 56 patients were analyzed. CIOM was observed in 23 presentations (32.9%), with a higher incidence associated with HSCT (17 of 35 presentations, 48.6%) than with IC (six of 35 presentations, 8.6%). The reactivation of HSV-1 was significantly associated with an increased incidence of CIOM after adjusting for age, sex, type of disease, and treatment stage. A higher HSV-1 viral load was associated with an increased incidence of CIOM. The presence of Candida was not associated with CIOM.
Conclusions: HSV-1 reactivation in the oral cavity was highly associated with CIOM in patients with HMs undergoing high-dose chemotherapy.

참고문헌 (Reference)

1 World Health Organization, "WHO Handbook for Reporting Results of Cancer Treatment"

2 Woo SB, "The role of herpes simplex virus in the development of oral mucositis in bone marrow transplant recipients" 66 : 2375-2379, 1990

3 Chen YK, "The impact of oral herpes simplex virus infection and candidiasis on chemotherapy-induced oral mucositis among patients with hematological malignancies" 30 : 753-759, 2011

4 Ruescher TJ, "The impact of mucositis on alpha-hemolytic streptococcal infection in patients undergoing autologous bone marrow transplantation for hematologic malignancies" 82 : 2275-2281, 1998

5 Redding SW, "Role of herpes simplex virus reactivation in chemotherapy-induced oral mucositis" 103-105, 1990

6 de Mendonca RM, "Prospective evaluation of HSV, Candida spp., and oral bacteria on the severity of oral mucositis in pediatric acute lymphoblastic leukemia" 20 : 1101-1107, 2012

7 Vanderas AP, "Progression of proximal caries in children with different caries indices : a 4-year radiographic study" 7 : 148-152, 2006

8 Lee JT, "Prevalence of antibody to herpes simplex virus" 31 : 38-46, 1993

9 Wald A, "Polymerase chain reaction for detection of herpes simplex virus(HSV)DNA on mucosal surfaces : comparison with HSV isolation in cell culture" 188 : 1345-1351, 2003

10 Sonis ST, "Perspectives on cancer therapy-induced mucosal injury : pathogenesis, measurement, epidemiology, and consequences for patients" 100 : 1995-2025, 2004

11 Stiff PJ, "Palifermin reduces patient-reported mouth and throat soreness and improves patient functioning in the hematopoietic stemcell transplantation setting" 24 : 5186-5193, 2006

12 Mendonca RM, "Oral mucositis in pediatric acute lymphoblastic leukemia patients : evaluation of microbiological and hematological factors" 32 : 322-330, 2015

13 Sonis ST, "Oral mucositis and the clinical and economic outcomes of hematopoietic stemcell transplantation" 19 : 2201-2205, 2001

14 Vera-Llonch M, "Oral mucositis and outcomes of allogeneic hematopoietic stem-cell transplantation in patients with hematologic malignancies" 15 : 491-496, 2007

15 Scully C, "Oral mucositis" 12 : 229-241, 2006

16 Epstein JB, "Mucositis in the cancer patient and immunosuppressed host" 21 : 503-522, 2007

17 Pico JL, "Mucositis : its occurrence, consequences, and treatment in the oncology setting" 3 : 446-451, 1998

18 Lalla RV, "MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy" 120 : 1453-1461, 2014

19 Vagliano L, "Incidence and severity of oral mucositis in patients undergoing haematopoietic SCT : results of a multicentre study" 46 : 727-732, 2011

20 Vokurka S, "Higher incidence of chemotherapy induced oral mucositis in females : a supplement of multivariate analysis to a randomized multicentre study" 14 : 974-976, 2006

21 Carrega G, "Herpes simplex virus and oral mucositis in children with cancer" 2 : 266-269, 1994

22 Bergmann OJ, "Herpes simplex virus and intraoral ulcers in immunocompromised patients with haematologic malignancies" 9 : 184-190, 1990

23 Tomblyn M, "Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients : a global perspective" 15 : 1143-1238, 2009

24 Jones JA, "Epidemiology of treatment-associated mucosal injury after treatment with newer regimens for lymphoma, breast, lung, or colorectal cancer" 14 : 505-515, 2006

25 Bubley GJ, "Effect of acyclovir on radiation-and chemotherapy-induced mouth lesions" 33 : 862-865, 1989

26 Freifeld AG, "Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer : 2010 update by the Infectious Diseases Society of America" 52 : 427-431, 2011

27 Nagel MA, "Burning mouth syndrome due to herpes simplex virus type 1" 2015 : 2015

28 Donnelly JP, "Antimicrobial therapy to prevent or treat oral mucositis" 3 : 405-412, 2003

29 Epstein JB, "Acyclovir prophylaxis of oral herpes virus during bone marrow transplantation" 32B : 158-162, 1996

30 Redding SW, "Acyclovir prophylaxis for oral herpes simplex virus infection in patients with bone marrow transplants" 67 : 680-683, 1989